Alliance for Clinical Trials in Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2011-01-01

Employees: 251

Market Cap: -

Website: https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Phase 2

Active, not recruiting

Conditions: Castration-Sensitive Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8

Interventions: Other: Pharmacotherapy Discontinuation
Other: Follow-Up
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2022-02-16

Last Posted Date: 2024-10-28

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 79

Registration Number: NCT05241860

Locations: 🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
🇺🇸
Flaget Memorial Hospital, Bardstown, Kentucky, United States
🇺🇸
State University of New York Upstate Medical University, Syracuse, New York, United States

and more 323 locations

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Phase 3

Recruiting

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Other: Informational Intervention
Behavioral: Smoking Cessation Intervention
Other: Health Promotion and Education
Other: Questionnaire Administration

First Posted Date: 2021-08-17

Last Posted Date: 2024-10-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 600

Registration Number: NCT05008848

Locations: 🇺🇸
Saint Mary's Hospital, Centralia, Illinois, United States
🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸
Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States

and more 178 locations

Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

Phase 3

Active, not recruiting

Conditions: Breast Carcinoma
Mastectomy Patient

Interventions: Other: Best Practice
Device: Wound Dressing Material
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-08-04

Last Posted Date: 2024-07-03

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 216

Registration Number: NCT04989504

Locations: 🇺🇸
Helen F Graham Cancer Center, Newark, Delaware, United States
🇺🇸
Saint Francis Cancer Center, Greenville, South Carolina, United States
🇺🇸
Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States

and more 46 locations

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Phase 3

Recruiting

Conditions: Anorexia
Hematopoietic and Lymphoid Cell Neoplasm
Advanced Malignant Solid Neoplasm

Interventions: Drug: Olanzapine
Drug: Megestrol Acetate
Other: Questionnaire Administration

First Posted Date: 2021-06-25

Last Posted Date: 2024-10-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 360

Registration Number: NCT04939090

Locations: 🇺🇸
Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States
🇺🇸
BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri, United States
🇺🇸
Billings Clinic Cancer Center, Billings, Montana, United States

and more 249 locations

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2

Recruiting

Conditions: Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Follicular T-Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Etoposide
Drug: Duvelisib
Drug: Oral azacitidine

First Posted Date: 2021-03-17

Last Posted Date: 2024-08-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 170

Registration Number: NCT04803201

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Memorial Hospital East, Shiloh, Illinois, United States
🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 74 locations

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

Phase 3

Recruiting

Conditions: BRCA1 Mutation
Breast Cancer
Breast Diseases
Breast Neoplasms
Breast Carcinoma
Neoplasms

Interventions: Drug: Placebo
Drug: Denosumab
Other: Quality-of-Life Assessment

First Posted Date: 2021-01-15

Last Posted Date: 2024-10-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 300

Registration Number: NCT04711109

Locations: 🇺🇸
Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers - Swedish, Englewood, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States

and more 44 locations

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Phase 3

Active, not recruiting

Conditions: Locally Advanced Urothelial Carcinoma
Locally Advanced Urethral Urothelial Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Locally Advanced Bladder Urothelial Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Nivolumab
Drug: Atezolizumab
Drug: Durvalumab
Drug: Avelumab

First Posted Date: 2020-11-20

Last Posted Date: 2024-07-31

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 3

Registration Number: NCT04637594

Locations: 🇺🇸
CHI Health Saint Francis, Grand Island, Nebraska, United States
🇺🇸
CHI Health Good Samaritan, Kearney, Nebraska, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 374 locations

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Carcinoma

Interventions: Drug: Placebo Administration
Drug: Oxybutynin Chloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-10-23

Last Posted Date: 2024-06-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 88

Registration Number: NCT04600336

Locations: 🇺🇸
McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa, United States
🇺🇸
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
🇺🇸
Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States

and more 100 locations

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

Not Applicable

Recruiting

Conditions: Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8

Interventions: Other: Decision Aid iCanDecide - ESE website
Other: Decision Aid iCanDecide - S website
Procedure: Therapeutic Conventional Surgery
Other: Training
Other: Media Intervention
Other: Interview
Other: Best Practice
Other: Survey Administration
Other: Quality-of-Life Assessment

First Posted Date: 2020-09-16

Last Posted Date: 2024-10-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 700

Registration Number: NCT04549571

Locations: 🇺🇸
Kaiser Permanente-Vallejo, Vallejo, California, United States
🇺🇸
Helen F Graham Cancer Center, Newark, Delaware, United States
🇺🇸
Beebe Health Campus, Rehoboth Beach, Delaware, United States

and more 24 locations

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Lung Adenocarcinoma
Stage IV Lung Cancer AJCC v8
Metastatic Lung Adenocarcinoma
Metastatic Lung Non-Small Cell Carcinoma
Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8

Interventions: Drug: Pembrolizumab
Other: Comprehensive Geriatric Assessment
Drug: Pemetrexed
Other: Questionnaire Administration
Drug: Carboplatin
Other: Quality-of-Life Assessment

First Posted Date: 2020-08-31

Last Posted Date: 2024-04-09

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 101

Registration Number: NCT04533451

Locations: 🇺🇸
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States
🇺🇸
Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States
🇺🇸
ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States

and more 502 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy